SynthesisBMJ global health2020
Tuberculosis case fatality in India: a systematic review and meta-analysis.
Synthesis in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prevalence and risks of tuberculosis multimorbidity in low-income and middle-income countries: a meta-review.BMJ open · 2022Pooled it
- Evaluating the nationwide availability of essential diagnostics for tuberculosis toward achieving a TB-free India.Microbiology spectrum · 2026Article
- Article
- Diet and nutrition status of adult multidrug-resistant tuberculosis cases, household controls, and community controls in Mumbai, India.PLOS global public health · 2026Article
- Article
- "Differentiated care is not a matter of feasibility but a necessity"- service providers' perception on initiating a comprehensive tuberculosis care package (CCp-K) to reduce deaths in Kerala, India.BMC health services research · 2025Article
- Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis.The Lancet. Global health · 2025Article
- Mortality and its influencing factors during anti-tuberculosis treatment in pulmonary tuberculosis patients in Hunan Province.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Review
- Evaluation of a results-based financing nutrition intervention for tuberculosis patients in Madhya Pradesh, India, implemented during the COVID-19 pandemic.BMC global and public health · 2023Article
- Better understanding extrapulmonary tuberculosis: A scoping review of public health impact in Pakistan, Afghanistan, India, and Bangladesh.Health science reports · 2023Article
- Characterising cause of death among people treated for drug-susceptible TB in India.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Tuberculosis and COVID-19: An epidemic submerged in the pandemic: A case series and review of current literature.Journal of family medicine and primary care · 2022Article
- Analyzing the attitude of Indian citizens during the second wave of COVID-19: A text analytics study.International journal of disaster risk reduction : IJDRR · 2022Article
- Addressing TB multimorbidity in policy and practice: An exploratory survey of TB providers in 27 high-TB burden countries.PLOS global public health · 2022Article
- Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus.Rheumatology international · 2021Article
- TB case fatality and recurrence in a private sector cohort in Mumbai, India.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021Article
- Status and challenges for tuberculosis control in India - Stakeholders' perspective.The Indian journal of tuberculosis · 2021Article
- COVID-19 & the National Tuberculosis Elimination Programme of India.The Indian journal of medical research · 2021Article
- Case fatality and recurrent tuberculosis among patients managed in the private sector: A cohort study in Patna, India.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The WHO End TB Strategy calls for a global reduction in the case fatality ratio (CFR) below 5%. India accounts for a third of global tuberculosis (TB) deaths. This systematic review estimated CFRs among Indian patients with TB both during and after treatment. Methods: We systematically searched Medline, Embase and Global Health for eligible studies published between 1 January 2006 and 8 January 2019, including both cohort studies and intervention study control arms that followed Indian patients with TB for fatality either during treatment or post-treatment. From relevant studies we extracted CFRs in addition to study demographics. Study quality was assessed using modified Scottish Intercollegiate Guidelines Network cohort criteria. Sufficiently homogenous studies were pooled using a random effect generalised linear mixed model. A meta-regression was performed to associate study characteristics with resulting CFRs. Results: 218 relevant studies were identified, of which 211 provided treatment phase CFRs. Most patients (92.4%) were treated in the public sector. Quality concerns were identified in 74% of papers. We estimated a pooled treatment phase CFR of 5.16% (95% CI 4.20% to 6.34%) which fell to 3.78% (2.77% to 5.16%) when restricted to 52 high-quality studies. Treatment phase CFRs were higher for paediatric (n=27, 6.50% (2.65% to 10.36%)), drug-resistant (n=43, 14.06% (10.15% to 19.49%)) and HIV-infected (n=35, 10.91% (7.68% to 15.50%)) patients. Nineteen post-treatment CFR studies were too heterogeneous to pool except when restricting to three high-quality studies (2.69% (-0.79% to 6.18%)). Poor study quality (OR=2.27 (2.01 to 2.57)) and tertiary centres patients (OR=1.15 (1.03 to 1.28)) were significantly associated with increased treatment phase case fatality. Conclusions: Case fatality is a critical measure of the quality of TB care. While India's treatment CFRs are in line with WHO targets, several key patient groups remain understudied and most studies suffer from methodological issues. Increased high-quality reporting on patient outcomes will help improve the evidence base on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.